BPC-157, Tesamorelin, and 5-Amino-1MQ: fat loss stack or hype?

What's this video probably claiming?

Based on the caption and creator context, Jonathan Coyle is presenting a five-compound protocol, BPC-157, Tesamorelin, 5-Amino-1MQ, NAD+, and Glutathione, as a personal regimen he uses to stay lean at 43. The framing is experiential and aspirational: a visible physique paired with a named compound stack implicitly suggests causation. The word "synergistic" is doing a lot of heavy lifting here. The claim architecture likely goes something like this: each compound handles a different lever (fat metabolism, cellular repair, detoxification), and together they create an outcome greater than the sum of their parts. That is a specific pharmacological assertion, not just a lifestyle anecdote. The audience is watching a compelling person attribute their body composition to a protocol they can presumably replicate. That is the claim worth examining.

What does the science actually show?

Let's take these one at a time. Tesamorelin has the strongest clinical backing of the group. It is FDA-approved as Egrifta for HIV-associated lipodystrophy, and trials in that population showed visceral fat reductions of roughly 15-20% over 26 weeks (Falutz et al., 2010, New England Journal of Medicine). Its use in otherwise healthy adults for aesthetic fat loss is off-label and extrapolated. BPC-157 has shown gut healing and anti-inflammatory effects in rodent models (Sikiric et al., 2018, Current Pharmaceutical Design), but zero completed human RCTs exist. 5-Amino-1MQ is a newer NNMT inhibitor showing fat mass reduction in mouse models (Neelakantan et al., 2019, Nature Communications), again with no published human trials. NAD+ precursors have modest human data on cellular energy and aging markers, but IV glutathione for systemic detoxification is largely unsupported by clinical evidence in healthy individuals.

Where does the social media noise diverge from clinical reality?

The gap is significant. Calling this combination "synergistic" implies studied interaction effects. No published research examines these five compounds together in humans. Each is being pulled from a different evidence tier, one FDA-approved drug, two compounds with only animal data, and two supplements with mixed or weak human evidence, and presented as a unified protocol. That is not how clinical pharmacology works. The word "detoxification" attached to glutathione is a red flag; the liver and kidneys handle detoxification, and healthy individuals do not accumulate toxins that IV glutathione resolves. Additionally, attributing a lean physique at 43 to a peptide stack, without controlling for diet, training, sleep, or genetics, is the oldest confounding variable problem in health content. One person's anecdote is not a protocol recommendation.

What should you actually know?

If you are interested in any of these compounds, the starting point is not a TikTok caption. Tesamorelin requires a prescription and has real side effects including fluid retention, joint pain, and potential glucose dysregulation (FDA prescribing information, 2010). BPC-157 and 5-Amino-1MQ are not FDA-approved for any indication; compounded versions exist in a regulatory gray area. The FDA issued warnings in 2023 about unapproved peptides in compounded products. NAD+ precursors like NMN or NR have the most accessible human data, though effect sizes on body composition specifically are modest. Before starting any of these, a conversation with a licensed clinician who can review your metabolic panel, body composition baseline, and actual health goals is not optional, it is the minimum standard. A compound that works in a mouse model or on one photogenic creator is not evidence it will work for you.